Deepa Prasad, outgoing vTv Therapeutics CEO
March 4, 2022 07:27 AM ESTUpdated 05:41 PM
People

Small biotech CEO ex­o­dus con­tin­ues as vTv, a trou­bled for­mer Alzheimer's play­er, sees chief leave af­ter just 4 months

Jason Mast

Editor

It’s been a bad cou­ple months for the heads of small, strug­gling biotechs.

On Fri­day, vTv ther­a­peu­tics, a North Car­oli­na com­pa­ny that once raised a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times